[go: up one dir, main page]

UY29249A1 - Agentes citotóxicos que comprenden taxanos nuevos - Google Patents

Agentes citotóxicos que comprenden taxanos nuevos

Info

Publication number
UY29249A1
UY29249A1 UY29249A UY29249A UY29249A1 UY 29249 A1 UY29249 A1 UY 29249A1 UY 29249 A UY29249 A UY 29249A UY 29249 A UY29249 A UY 29249A UY 29249 A1 UY29249 A1 UY 29249A1
Authority
UY
Uruguay
Prior art keywords
cytotoxic agents
taxans
therapeutic use
new
understanding new
Prior art date
Application number
UY29249A
Other languages
English (en)
Inventor
Ravi V J Chari
Commercon Alain
Michael L Miller
Baloglu Erkan
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29249(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of UY29249A1 publication Critical patent/UY29249A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a nuevos agentes citotóxicos y su utilización terapéutica. Más específicamente, la invención se refiere a nuevos agentes citotóxicos que comprenden taxanos y su utilización terapéutica. Estos nuevos agentes citotóxicos tienen utilización terapéutica como resultado de proporcionar taxanos a una población celular específica de forma dirigida mediante enlace químico del taxano con el agente de unión a la célula.
UY29249A 2004-12-07 2005-12-07 Agentes citotóxicos que comprenden taxanos nuevos UY29249A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04292898A EP1669358A1 (en) 2004-12-07 2004-12-07 Cytotoxic agents comprising new taxanes

Publications (1)

Publication Number Publication Date
UY29249A1 true UY29249A1 (es) 2006-06-30

Family

ID=34931583

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29249A UY29249A1 (es) 2004-12-07 2005-12-07 Agentes citotóxicos que comprenden taxanos nuevos

Country Status (22)

Country Link
US (1) US7667054B2 (es)
EP (2) EP1669358A1 (es)
JP (1) JP2008523019A (es)
KR (1) KR20070085781A (es)
CN (1) CN101094857A (es)
AR (1) AR054100A1 (es)
AU (1) AU2005313444B2 (es)
BR (1) BRPI0518869A2 (es)
CA (1) CA2588587A1 (es)
DO (1) DOP2005000248A (es)
EA (1) EA012625B1 (es)
IL (1) IL183404A0 (es)
MA (1) MA29103B1 (es)
MX (1) MX2007006765A (es)
MY (1) MY144632A (es)
NO (1) NO20073033L (es)
NZ (1) NZ555406A (es)
PE (2) PE20110001A1 (es)
TW (1) TW200637836A (es)
UY (1) UY29249A1 (es)
WO (1) WO2006061258A2 (es)
ZA (1) ZA200704790B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
PT1392359E (pt) 2001-05-11 2010-01-27 Ludwig Inst For Cancer Res Ltd Proteínas de ligação específica e suas utilizações
MX338185B (es) * 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
AU2008227123B2 (en) * 2007-03-15 2014-03-27 Ludwig Institute For Cancer Research Ltd. Treatment method using EGFR antibodies and src inhibitors and related formulations
JP5532486B2 (ja) 2007-08-14 2014-06-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｅｇｆ受容体を標的とするモノクローナル抗体１７５ならびにその誘導体および用途
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
CN101851231A (zh) * 2010-05-27 2010-10-06 东北林业大学 一种多西紫杉醇新衍生物的合成方法及其在制备抗肿瘤药物中的应用
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
WO2014009774A1 (en) 2012-07-12 2014-01-16 Hangzhou Dac Biotech Co., Ltd Conjugates of cell binding molecules with cytotoxic agents
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
CN104693156A (zh) * 2014-10-22 2015-06-10 上海大学 9,10-二羟基-1-去氧紫杉醇类似物及其制备方法
EP3319936B1 (en) 2015-07-12 2025-12-17 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20220147721A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
HK1049997B (en) * 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
BR0313197A (pt) * 2002-08-02 2005-08-09 Immunogen Inc Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico

Also Published As

Publication number Publication date
EP1669358A1 (en) 2006-06-14
ZA200704790B (en) 2008-08-27
AU2005313444B2 (en) 2011-11-10
EA200701251A1 (ru) 2007-12-28
CN101094857A (zh) 2007-12-26
WO2006061258A2 (en) 2006-06-15
PE20061060A1 (es) 2006-11-14
MA29103B1 (fr) 2007-12-03
KR20070085781A (ko) 2007-08-27
US20060178427A1 (en) 2006-08-10
IL183404A0 (en) 2007-10-31
EA012625B1 (ru) 2009-10-30
EP1824858A2 (en) 2007-08-29
BRPI0518869A2 (pt) 2008-12-16
TW200637836A (en) 2006-11-01
NZ555406A (en) 2011-02-25
WO2006061258A3 (en) 2006-09-28
US7667054B2 (en) 2010-02-23
CA2588587A1 (en) 2006-06-15
DOP2005000248A (es) 2007-02-15
PE20110001A1 (es) 2011-01-21
MY144632A (en) 2011-10-14
AR054100A1 (es) 2007-06-06
MX2007006765A (es) 2007-08-16
NO20073033L (no) 2007-08-28
AU2005313444A1 (en) 2006-06-15
JP2008523019A (ja) 2008-07-03

Similar Documents

Publication Publication Date Title
UY29249A1 (es) Agentes citotóxicos que comprenden taxanos nuevos
TW200740956A (en) Organic electroluminescent devices
UY29250A1 (es) Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2.-
EA201070544A1 (ru) Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
GT201000008A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina y su uso terapeutico
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
CO6351786A2 (es) Inkibidores de la cinasa map p38
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
NO20080068L (no) Topisk unguale formuleringer
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
SV2009003393A (es) Polipeptidos de factor vii modificaciones y usos de los mismos
UY31484A1 (es) Piperidinas heteroaril-sustituidas
CL2013000718A1 (es) Un complejo de inclusion que comprende a) una ciclodextrina, b) fulvestrant y c) un portador; su metodo de preparacion; formulacion y forma de dosificacion que comprende al complejo; preparacion que comprende al complejo o a la formulación; y su uso en el tratamiento del cancer y lupus eritematoso sistemico, entre otras enfermedades.
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
CU24349B1 (es) Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
ATE528013T1 (de) Impfstoff-zusammensetzungen
DOP2009000208A (es) Métodos de tratamiento del cáncer mediante administración de combinaciones de il-18 humana
AR114148A2 (es) Composición terapéutica saborizada basada en arcilla
TW200735438A (en) Organic electroluminescent devices
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
CL2011000614A1 (es) Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras.
UY28746A1 (es) Moduladores de receptores de androgenos